SLU-PP-332: The 'Exercise Pill' Mechanism, Tested in Mice
A pan-ERR agonist nicknamed the 'exercise pill' — reduced fat mass and raised fatty-acid oxidation in obese mice, with zero human trials as of 2026.
What is SLU-PP-332?
SLU-PP-332 is a small-molecule pan-ERR (estrogen-related receptor) agonist that reproduces some of the metabolic gene-expression changes seen with endurance exercise — increasing fatty-acid oxidation, mitochondrial content, and energy expenditure. In diet-induced-obese mice, it reduced body weight (roughly 12%) and fat-mass accumulation without reducing food intake, suggesting a metabolic rather than appetite-suppressing effect, distinct from the GLP-1 class. As of 2026 it has never been studied in humans — all supporting data comes from mouse and cell experiments.
Quick facts
- Class
- Pan-ERR (estrogen-related receptor) agonist — small molecule, not a peptide
- Brand Names
- No trademarked brand — sold as a research compound
- Legal Status
- Not FDA-approved for human use — research use only (RUO). No human trials published as of 2026
- Category
- Metabolic / Exercise Mimetic
- Storage
- Store the lyophilized vial refrigerated (2-8°C) or at -20°C, away from light. Once reconstituted, keep refrigerated at 2-8°C and use promptly.
Dosing at a glance
50mg vial + 2mL bacteriostatic water = 25mg/mL. Run the numbers in the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
What the evidence supports
| Claim | Grade | Basis |
|---|---|---|
| Weight Loss | Dgrade | Billon 2024 (J Pharmacol Exp Ther): reduced body weight/fat-mass in obese mice without reduced food intake. No human trials. |
| Body Composition | Dgrade | Raised fatty-acid oxidation, energy expenditure, and oxidative muscle fiber content in mice — an 'endurance training' metabolic profile, animal-only. |
SLU-PP-332 Mechanism of Action
Reproducing Exercise's Metabolic Gene Program
SLU-PP-332 activates all three ERR (estrogen-related receptor) subtypes — nuclear receptors that sit downstream of PGC-1α, the master regulator of mitochondrial biogenesis normally activated by endurance exercise. Pharmacologically activating ERR reproduces part of that gene-expression program — increased fatty-acid oxidation, mitochondrial content, and oxidative muscle fiber type — without requiring the exercise itself, earning it the informal nickname 'exercise in a pill.'
Metabolic, Not Appetite-Suppressing
Unlike GLP-1 class drugs, SLU-PP-332's weight effects in mice occurred without reduced food intake — the mechanism is about increasing energy expenditure and fat oxidation, not suppressing appetite. This makes it mechanistically distinct from the semaglutide/tirzepatide family despite both being studied for weight-related outcomes.
SLU-PP-332 Dosage and Protocols
Research Protocol Range
Research-vendor products are commonly dosed at 25-50mg subcutaneous once daily. Since no human trial exists, this range reflects informal research-community convention extrapolated from mouse dosing, not validated human guidance.
SLU-PP-332 Side Effects and Safety
No Human Safety Data
Because no human trial has been published, there is no characterized human side-effect profile for SLU-PP-332. Active malignancy is treated as a precautionary contraindication given the broad nuclear-receptor mechanism affecting cellular metabolism genome-wide.
SLU-PP-332 Research Evidence
A Consistent Mouse-Model Signal
Billon et al. (2024, J Pharmacol Exp Ther) found SLU-PP-332 reduced body weight (~12%) and fat-mass accumulation in diet-induced-obese mice without reducing food intake. A companion 2023 study (ACS Chem Biol) found it increased oxidative type IIa muscle fibers and mitochondrial content — consistent with a genuine endurance-training-like metabolic shift, at least in mice.
Regulatory and Legal Status
SLU-PP-332 is not FDA-approved and has never been studied in humans as of 2026 — every claim rests on mouse and cell data. It is sold exclusively as a research-grade compound (RUO). Researchers and users should verify the legal status of SLU-PP-332 in their jurisdiction prior to purchase or use, and should weigh the complete absence of human data accordingly.
SLU-PP-332 Stacking and Combinations
SLU-PP-332 + SLU-PP-915
SLU-PP-332 is sometimes discussed alongside its orally-active successor compound SLU-PP-915 in research contexts, though they're typically used as alternatives (injectable vs. oral) rather than combined — both target the same ERR pathway.
SLU-PP-332 Pharmacokinetics
Not Established in Humans
No human pharmacokinetic study — absorption, half-life, clearance — has been published for SLU-PP-332. Notably, the original compound required injection to show effects in mice, which is part of what motivated development of the orally-active follow-on compound, SLU-PP-915.
Contraindications
- pregnancy
- active malignancy
Trials and reviews
- Billon metabolic syndromeJ Pharmacol Exp Ther2024
Reduced fat-mass accumulation, raised fatty-acid oxidation in obese mice
- Billon ERR agonist / exerciseACS Chem Biol2023
Increased oxidative type IIa fibers + mitochondrial content
Frequently asked questions
What is a typical SLU-PP-332 dose?
Published research protocols report 25–50 mg, 1x daily. This is the range described in the literature, not a recommendation.
What is the half-life of SLU-PP-332?
Not established in humans.
Is SLU-PP-332 backed by strong evidence?
SLU-PP-332 carries a REGEN research grade of D. REGEN Research Tier D — mouse and cell data only, no published human trials as of 2026.
How is SLU-PP-332 administered?
Routes reported in the literature: subcutaneous.
Who should avoid SLU-PP-332?
Contraindications noted in the literature include pregnancy, active malignancy.
References
- SLU-PP-332 pan-ERR agonist metabolic syndrome study · Billon C, et al. · 2024